CSBio Appears in 2.6% of AI Answers. Here's Our Five-Step Plan to Improve Its AI Visibility.
This report supports CiteWorks Studio's examination of how AI search is recommending Peptide API Manufacturing. For more detail, you can also read Peptide API Manufacturing: AI Visibility Discovery Index.
On this report
Browse sections
- Answer Capsule
- Current AI visibility
- What changed since last month
- Next Step
- Step 1. Measure
- Step 2. Make the website consistent
- Step 3. Align the external narrative
- Step 4. Optimize priority company pages
- Step 5. Publish around buyer questions
- Our 90-day action plan
- Methodology
- Our first three priorities
- Related research
- Learn More
Key Takeaways
- CSBio appears in 2.64% of benchmark answers, with 1.98% recommending it, but it has no Top 3 or first-place placements.
- The main issue is reach and shortlist inclusion, not tone, since most CSBio mentions are positive.
- No conflicting claims were recorded in this sample, so the first step is to verify facts before proposing page or source changes.
- Buyer questions center on US peptide manufacturers, legitimacy, and scale, which should guide new content briefs.
Answer Capsule
In November 2026, CSBio appeared in 8 of 303 AI answers included in the Peptide API Manufacturing benchmark (2.64%). It received 6 recommendations (1.98%), with 0 Top 3 placements and 0 first-place recommendations. A mention means the company appeared in an answer; a recommendation means the answer affirmatively endorsed it.
Our plan compares the company with its competitors, checks conflicting AI claims against reliable sources, and identifies website pages, third-party sources and buyer questions to address. This edition establishes a research baseline. It does not claim a change from earlier editions measured on a different basis. Conflicting AI claims require verification before corrections are proposed.
Current AI visibility
Questions This Section Answers
- How do CSBio mentions, recommendations and placements compare with its Peptide API Manufacturing peers?
CSBio recorded 8 mentions (2.64%) and 6 recommendations (1.98%) across 303 answers included in the benchmark. Top 3 placements numbered 0; first-place recommendations numbered 0. Framing among its mentions was 6 positive, 2 neutral and 0 negative.
Rank | Company | Mentions | Mention rate | Recommendations | Recommendation rate | Top 3 | Top 3 rate | #1 | #1 rate |
|---|---|---|---|---|---|---|---|---|---|
1 | Bachem | 258 | 85.15% | 173 | 57.10% | 152 | 50.17% | 113 | 37.29% |
2 | AmbioPharm | 110 | 36.30% | 82 | 27.06% | 63 | 20.79% | 8 | 2.64% |
3 | Biosynth Peptide Division | 71 | 23.43% | 63 | 20.79% | 42 | 13.86% | 6 | 1.98% |
4 | PolyPeptide Group | 70 | 23.10% | 46 | 15.18% | 34 | 11.22% | 1 | 0.33% |
5 | CPC Scientific | 53 | 17.49% | 32 | 10.56% | 18 | 5.94% | 3 | 0.99% |
6 | CordenPharma Peptides | 49 | 16.17% | 21 | 6.93% | 16 | 5.28% | 1 | 0.33% |
7 | CSBio | 8 | 2.64% | 6 | 1.98% | 0 | 0.00% | 0 | 0.00% |
CSBio appears in a small share of the benchmark answers, yet most of those appearances also carried a recommendation. That is a meaningful signal: when the company surfaces, the answer tends to speak well of it. The gap is reach, not tone.
The position picture is the harder one. CSBio recorded no shortlist placements and no first-place placements, so its presence sits outside the ranked group that buyers see first. Recommendations without position mean the company is named approvingly but rarely as a leading option.
The practical implication is that CSBio's problem is being considered, not being trusted. Work should focus on earning inclusion in shortlists where larger peptide manufacturers dominate, rather than on repairing sentiment that already reads positively.
What changed since last month
Questions This Section Answers
- How did CSBio counts and coverage differ across the available monthly snapshots?
Metric | Nov 2026 |
|---|---|
Mentions | 8 / 303 (2.64%) |
Recommendations | 6 / 303 (1.98%) |
Top 3 recommendations | 0 / 303 (0.00%) |
#1 recommendations | 0 / 303 (0.00%) |
Only months with verified results are shown. Monthly sample coverage is listed in Methodology.
This edition establishes a broader research baseline. Earlier editions used a narrower set of questions, so their figures are not treated as a performance trend.
This edition is the first broad baseline, so the monthly figures describe a starting position rather than a movement from earlier months. Earlier editions used a narrower question set and are not comparable, which means no trend should be read into the current totals.
That matters for how the client uses this report. The numbers to watch are the ones future editions will measure against the same screening scope, not the archived figures. Any apparent change between editions should be treated cautiously until several comparable months exist.
For now, the baseline serves as a reference point. The agency would record it as the anchor for later comparison and resist drawing conclusions about direction from a single month of coverage.
AI recommendation trend
Observed recommendation rate (%), Nov 2026
- CSBiono changeNov 20261.98%
Separate selected monthly samples. Missing points are unavailable, not zero. Provider/prompt equivalence is unverified; rate movement does not demonstrate causation.
/ Take the next step
Want to Understand Your AI Citation Footprint?
We start every engagement with a full audit of how AI systems reference your brand today.
Measurable, Repeatable Programme
Build a durable foundation of credible citations that compounds over time and continues to influence AI answers as new queries emerge
Citation Architecture Review
Identify which high-authority community sources are and aren't working in your favour across AI platforms.
AI Visibility Audit
Understand exactly how LLMs are referencing your brand today and which sources are shaping those answers.
Step 1. Measure
Questions This Section Answers
- What should the agency measure and verify first for CSBio?
AI answers contained 0 conflicting claims about CSBio: 0 critical, 0 high, 0 medium, 0 low. Of these, 0 were rated critical or high priority; the critical claims are included in that total. These ratings help prioritize fact-checking. They do not establish that a company or publisher made an error.
With no conflicting claims recorded about CSBio, the fact-checking workload is light, but the measurement step still has value. A visibility comparison against the leading peptide manufacturers shows where CSBio sits in answer coverage and where the distance is greatest.
Pairing that comparison with a short list of claims worth verifying gives the client a clear order of work. The absence of flagged claims does not prove the answers are accurate; it means nothing in this sample required escalation.
The proposed work is a baseline scorecard and a scoped review list, each item assigned an owner and an evidence requirement. That keeps measurement separate from any later correction decisions.
Step 2. Make the website consistent
Questions This Section Answers
- Which recorded claim differences about CSBio should be verified before proposed page edits?
No results are available for this part of the analysis.
Both columns quote AI answers, not verified company facts. Resolve the entity, date and source before deciding whether a correction is warranted; different dates can explain an apparent conflict.
No disputed topics were supplied for this part of the analysis, so there is nothing to verify against the website at this stage. The consistency step therefore starts with entity and date checks rather than with page rewrites.
Where a claim does surface later, the first question is whether the company, product and date actually match CSBio. Different dates or a similarly named entity can create an apparent conflict that is not one.
Proposed work is conditional: confirm the facts against primary sources, then draft page briefs only for confirmed gaps. No correction should be requested until that verification is complete.
Step 3. Align the external narrative
Questions This Section Answers
- Which cited third-party pages are relevant to fact review for CSBio?
Cited page selected for review | Citation appearances in all captured answers | Answers mentioning the company | Conflicting claims linked to this page |
|---|---|---|---|
https://bachem.com/ | 99 | 4 | 0 |
https://biosynth.com/peptides | 70 | 2 | 0 |
https://ambiopharm.com/ | 48 | 2 | 0 |
https://app.biopharmiq.com/company-lists-all/list-of-peptide-therapies-companies-in-united-states | 8 | 2 | 0 |
https://biotech-careers.org/business-area/peptides | 4 | 2 | 0 |
https://cetaf.org/trusted-us-peptide-companies-hub/ | 2 | 2 | 0 |
These pages were selected because they relate to the company in the captured answers. Their current contents still need checking before any correction request. A page linked to a conflicting claim is not necessarily its cause, and the same answer may contribute to more than one row.
The cited pages selected for review are mostly competitor and directory sites, and none carries a conflicting claim linked to CSBio. Citation frequency alone does not show that a page shaped an answer, so these are review candidates rather than targets for correction requests.
The useful work is to check what each page currently says about CSBio and whether it is accurate and current. Where a page is a directory or list, a factual update request may be reasonable; where it is a competitor site, expectations should be modest.
Proposed work is a prioritized source review with evidence-backed requests, tracked separately from responses. Publisher control is never assumed.
Step 4. Optimize priority company pages
Questions This Section Answers
- Which observed CSBio website pages should receive review briefs?
Company website page | Citation appearances in all captured answers | Benchmark answers citing the page | Recommending answers citing the page |
|---|---|---|---|
https://csbio.com/blog/choosing-a-peptide-synthesizer | 2 | 0 | 0 |
The company's website was cited 2 times across 1 distinct page addresses; the table shows 1 pages selected for review. Zeros in the answer columns mean no matching answers were recorded. A cited page is not automatically a page that accompanied a recommendation.
Only one CSBio page was selected for review, and it recorded no benchmark answers citing it in either the general or recommending columns. That does not mean the page is weak; it means this sample gives little evidence about its role.
The page concerns choosing a peptide synthesizer, which is closer to equipment selection than to manufacturer shortlisting. A page brief should therefore start from approved company facts and the questions buyers actually ask, not from assumptions about why the page was or was not cited.
Proposed work is a brief built on verified facts and audience questions, with existing coverage checked before any new page is suggested.
Step 5. Publish around buyer questions
Questions This Section Answers
- Which observed buyer questions support content briefs for CSBio?
Question observed in the research | Benchmark answers to this question | Company mentions | Company recommendations |
|---|---|---|---|
What are the best peptide companies in the US? | 4 | 1 | 1 |
What companies sell the most peptides? | 5 | 1 | 1 |
What is the most legit peptide company? | 4 | 1 | 1 |
Who manufactures peptides in the USA? | 3 | 1 | 1 |
peptide companies | 2 | 1 | 1 |
peptide synthesis company | 2 | 1 | 1 |
Who manufactures peptides in the US? | 5 | 2 | 0 |
These are recorded answer observations, not search volume, verified demand, or proof of missing website content.
The recorded questions cluster around US peptide manufacturers, legitimacy and scale. CSBio appeared in answers to most of them, and in several the appearance also carried a recommendation, though one manufacturer question produced mentions without endorsement.
These are answer observations, not search volume or proof that the website lacks content. The pattern does suggest that buyer-question content on manufacturing location, legitimacy signals and scale would be worth briefing.
Proposed work is a set of content briefs tied to these questions, each checked against existing pages first so the agency adds substance rather than duplicates what CSBio already publishes.
Our 90-day action plan
Questions This Section Answers
- How should the agency sequence the proposed CSBio work and judge completion?
Period | Deliverable | Completion criterion |
|---|---|---|
Days 1–30 | Baseline scorecard, scoped fact-review register and page/source shortlist | Each record has an owner, evidence requirement and review status |
Days 31–60 | Approved page briefs and justified publisher requests | Separate confirmed edits, no-change decisions, requests and responses |
Days 61–90 | Buyer-content briefs and a fresh scorecard | Record work completed separately from measured answer outcomes and comparability limits |
The first month establishes the baseline scorecard, a scoped fact-review list and a shortlist of pages and sources, each with an owner and review status. This depends on the client confirming which facts are approved for use.
The second month turns confirmed findings into page briefs and justified publisher requests, with confirmed edits, no-change decisions and responses recorded separately. The third month adds buyer-content briefs and a fresh scorecard.
Delivered work is recorded apart from measured answer outcomes. Completing briefs or requests does not establish that visibility changed, and later comparisons carry the same scope limits as this baseline.
Methodology
Questions This Section Answers
- How are CSBio answer metrics and citation populations defined?
This report covers 2026-11. The exact dates when the original AI answers were collected have not been verified. The visibility rates use 303 answers that met the benchmark's inclusion rules. A company is recommended only when the answer both endorses it and uses positive wording. Top 3 and first-place counts are part of those recommendations, not extra recommendations.
An answer can mention or recommend several companies, so company counts cannot be added to find the number of distinct answers. The net sentiment score is positive minus negative mentions, divided by all company mentions; it describes answer wording, not customer satisfaction.
The wider citation analysis covers 359 captured answers and 2381 appearances of cited URLs. Citation appearances across all captured answers differ from the number of benchmark answers citing a page and the number that also recommend a company. The current contents of cited pages and disputed company claims still need independent verification.
Monthly sample coverage:
Reporting month | Answers included | AI services covered | Services |
|---|---|---|---|
Nov 2026 | 303 | 6 | ChatGPT, Copilot, Gemini, Google AI Mode, Google AI Overviews, Perplexity |
Earlier editions (July 2026, August 2026, September 2026 and October 2026) used a narrower set of questions. This edition includes all captured answers screened as relevant and establishes a broader baseline. Earlier figures remain in the archive; they are not used to claim a change in performance.
Future editions using the same screening scope can be compared against this baseline.
The benchmark covers answers that met inclusion rules, and a company counts as recommended only when an answer endorses it with positive wording. Shortlist and first-place counts sit inside recommendations rather than adding to them.
Answers can name several companies, so company totals cannot be summed into distinct answer counts. Sentiment describes answer wording, not customer satisfaction. Collection dates for the original answers are unverified, and cited pages still need independent checking.
This edition sets a broader baseline; earlier editions used a narrower question set and are not treated as a trend.
Our first three priorities
First, lock the baseline and confirm which CSBio facts are approved, so later briefs and any source requests rest on verified material rather than on answer text.
Second, review the selected external pages for accuracy about CSBio and prepare evidence-backed requests only where a factual gap is confirmed. Keep directory and competitor pages in separate tracks with realistic expectations.
Third, brief buyer-question content on US manufacturing, legitimacy and scale, checking existing pages first. These steps target reach and shortlist inclusion, the areas where the evidence shows the clearest distance from leading manufacturers.
Related research
This report supports CiteWorks Studio's examination of how AI search is recommending Peptide API Manufacturing. For more detail, you can also read Peptide API Manufacturing: AI Visibility Discovery Index.
/ Learn More
Understanding AI search visibility.
AI search experiences create answers by pulling information from many places online and summarizing it into a single response.


